Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that develops, discovers and commercializes medicines in the areas of unmet medical need across the United States, Europe and other international markets. The company’s portfolio of products includes medicines for the treatment of HIV/AIDS, coronavirus disease 2019, liver diseases, hematology, oncology and cell therapy, pulmonary arterial hypertension, chronic angina and serious invasive fungal infections.

Gilead Sciences, Inc. has collaborations with Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc. and Merck & Co, Inc.

The company’s products for the treatment of HIV/AIDS include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild and Atripla. Its products for the treatment of coronavirus disease 2019 include Veklury, an injection for intravenous use. Its products for the treatment of liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy and Viread. Its products for the treatment of hematology, oncology and cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Its product for the treatment of pulmonary arterial hypertension is Letairis, an oral formulation. Its product for the treatment of chronic angina is Ranexa, an oral formulation. Its product for the treatment of serious invasive fungal infections is AmBisome, a liposomal formulation.

Gilead Sciences, Inc. was incorporated in 1987 and is headquartered in Foster City, California. The company has three research and manufacturing facilities located in California, North Carolina and Scotland, and markets its products in more than 125 countries.